

ASSESSMENT OF RELATIONSHIP BETWEEN THE DOSE OF INTRAVENOUS METHYLPREDNISOLONE FOR TREATMENT RELAPSES OF MULTIPLE SCLEROSIS AND THE SIDE EFFECTS IN IRAQI PATIENTS

¹*Zainab Ali Abbood, ²Nawfal Madi Sheaheed and ³Hayder Fadhil Lateef

¹(Clinical Pharmacy Department, College of Pharmacy/ Baghdad University, Baghdad, Iraq).

^{2,3}(Baghdad Teaching Hospital, Medical City, Baghdad, Iraq).

Article Received on
17 Aug. 2016,

Revised on 07 Sept. 2016,
Accepted on 27 Sept. 2016

DOI: 10.20959/wjpr201610-7171

*Corresponding Author

Zainab Ali Abbood

(Clinical Pharmacy
Department, College of
Pharmacy/ Baghdad
University, Baghdad, Iraq).

ABSTRACT

Background: Multiple Sclerosis, a chronic inflammatory and neurodegenerative disease of the central nervous system, characterized by recurrent relapses of central nervous system inflammation ranging from mild to severely disabling. Relapses have treated with steroids to reduce inflammation and hasten recovery. However, the commonly used intravenous methylprednisolone in a dose 500mg_1000mg for 5days. **Objectives:** Assessment of relationship between the dose of intravenous methylprednisolone (500mg) and (1000mg) and side effects for treatment of patients with relapses of multiple sclerosis.

Methods: A prospective case controlled study was carried on 40

patients who had multiple sclerosis relapse confirmed by kuratzke expanded disability status scale. Patients were divided into 2 groups first group involved 20 patients treated with (500 mg IV methylprednisolone) for 5 days. The second group involved 20 patients treated with (1000mg IV methylprednisolone) for 5days. Serum random blood sugar, WBC counts before and after 1 and 6 weeks of the study and clinical examination for side effects. **Results:** The results showed that a non-significant difference WBC counts, while there was a significant increase in Serum random blood sugar level in group 2 after one week of treatment with 1000mg IV methylprednisolone for 5 days in comparison with pretreatment. However, there was a non-significant difference in Serum random blood sugar and WBC counts in group 1 after one week of treatment with 500mg IV methylprednisolone for 5 days in comparison with pretreatment. After six weeks of treatment, there was a non-significant change in Serum random blood sugar and WBC counts for patients in both treated groups compared to pre-

treatment. The laboratory assessments and clinical examination show that group 2 had more side effect than group 1. **Conclusion:** It seems from this short study that methylprednisolone in a dose of 500mg (IV) daily for 5day to patient with multiple sclerosis had fewer side effects than dose of 1000mg (IV) for 5 days.

KEYWORD: Multiple Sclerosis (MS), methylprednisolone, random blood sugar, WBC.

1. INTRODUCTION

Multiple sclerosis, also known as disseminated sclerosis or encephalomyelitis disseminate. The insulating covers of nerve cells in the brain and spinal cord damaged in an inflammatory disease. This damage disrupts the ability of parts of the nervous system to communicate and resulting in a wide range of signs and symptoms.^{[1],[2]} Lesions of MS typically occur at different times and in different central nervous system CNS locations (i.e., disseminated in time and space). Multiple sclerosis takes several forms, with new symptoms in either isolated attacks (relapsing forms) or building up over time (progressive forms). Between attacks, symptoms may disappear completely; or permanent neurological problems often occur, especially as the disease advances.^[3] The main symptoms of MS was optic neuritis, sensory loss, weakness and paresthesia.^[4] Measure disability and severity by the expanded disability status scale (EDSS).^[5]

Relapsing defined as “the patient-reported symptoms or objectively observed signs typical of an acute inflammatory demyelinating event in the CNS, current or historical, with duration of at least 24 hours, in absence of fever or infection.”^[6]

Mild acute exacerbations that do not produce functional decline may not require treatment. When functional ability is affected, the standard intervention is intravenous injection of high-dose corticosteroids.^[7] Intravenous methylprednisolone has been show to shorten the duration of acute exacerbations.^[8] The mechanism of action of corticosteroids used for acute relapses is not completely clear, but may involve the following actions:

Prevention of inflammatory cytokine activation, Inhibition of T-cell activation, prevention of immune cells from entering the CNS and Increased death of activated immune cells. Corticosteroids hasten functional recovery after relapses.^{[9],[10]}

1.1 Aim of the study

The present study designed to assessment of relationship between the dose of intravenous methylprednisolone (500mg) and (1000mg) and side effects for treatment of patients with relapses of multiple sclerosis.

2. PATIENTS AND METHODS

2.1 Patient

Forty MS patients with relapse (8 male, 32 female) were participated in this study, ethical clearance to conduct the research was sought and obtained from the patients. Data were collected through direct interview with the patient with the following inclusion criteria mean age 31.725 ± 0.914 years and mean duration of MS 3.179 ± 0.505 years. They assigned to receive either 500mg or 1000mg methylprednisolone. The study is carried out in Baghdad medical city during the period from November 2014 to May 2015. Patients undergoing clinical examination by measure (EDSS) in the multiple sclerosis unit of the hospital as well as in private clinic; a senior physician selected patients. The exclusion criteria includes if patients have other diseases like diabetic mellitus, cardiovascular, CNS, renal diseases and lactating or pregnant women.

Table (1) Chemicals, Drugs and their suppliers.

Chemicals	Suppliers
Methylprednisolone vial (500mg IV)	Pfizer
Urine strips test	Chungdo pharm, Korea

Table (2) Instruments used in this study and their suppliers.

Instruments	Suppliers
Auto vortex	Stuart Scientific, U.K
Blood collection plain tube	AFMH, England
Centrifuge-Universal 16A	Hettich, Germany
Distiller	Gallenkamp, U.K
EDTA containing tubes	AFMH, England
ELx 800 universal micro plate reader	Bio-Tek instruments, INC. USA
Fine and adjustable micropipettes and multichannel micropipettes	Gilson, France
Hamilton syringes	Hamilton PB 600, Bonaduz AG, Switzerland
Incubator	Gallenkamp, U.K
Oven	Memmert, Germany
pH meter	Jenway, Germany
Printer Epson	UK
Refrigerator	Arcelik, Turkey
Shaker	Khan Shaker , Italy
Spectrophotometer-CE 1011	Cecil, England
Water-bath	K&K, Korea

2.2 EDSS measurement

We can measure the disability of patient in acute attack MS and response to the treatment by calculate the kuratzke expanded disability status scale (EDSS)^[5]:

Table (3) expanded disability status scale (EDSS).

0.0	Normal neurologic exam (all grade 0 in functional status [FS])
1.0	No disability, minimal signs in one FS (i.e., grade 1)
1.5	No disability, minimal signs in more than one FS (more than one grade 1)
2.0	Minimal disability in one FS (one FS grade 2, others 0 or 1)
2.5	Minimal disability in two FS (two FS grade 2, others 0 or 1)
3.0	Moderate disability in one FS (one FS grade 3, others 0 or 1) or mild disability in three or four FS (three/four FS grade 2, others 0 or 1) though fully ambulatory
3.5	Fully ambulatory but with moderate disability in one FS (one grade 3) and one or two FS grade 2; or two FS grade 3; or five FS grade 2 (others 0 or 1)
4.0	Ambulatory without aid or rest for ~500 m
4.5	Ambulatory without aid or rest for ~300 m
5.0	Ambulatory without aid or rest for ~200 m
5.5	Ambulatory without aid or rest for ~100 m
6.0	Unilateral assistance required to walk about 100 m with or without resting
6.5	Constant bilateral assistance required to walk about 20 m without resting
7.0	Unable to walk beyond about 5 m even with aid; essentially restricted to wheelchair; wheels self and transfers alone
7.5	Unable to take more than a few steps; restricted to wheelchair; may need aid to transfer
8.0	Essentially restricted to bed or chair or perambulated in wheelchair, but out of bed most of day; retains many self-care functions; generally has effective use of arms
8.5	essentially restricted to bed much of the day; has some effective use of arm(s); retains some self-care functions
9.0	Helpless bed patient; can communicate and eat
9.5	totally helpless bed patient; unable to communicate or eat
10.0	Death due to MS

Functional Status (FS) Score

Table (4) Functional Status (FS) Score.

A. Pyramidal functions	
0	Normal
1	Abnormal signs without disability
2	Minimal disability
3	Mild or moderate Paraparesis or hemiparesis, or severe monoparesis
4	Marked paraparesis or hemiparesis, moderate quadriparesis, or monoplegia
5	Paraplegia, hemiplegia, or marked quadriparesis
6	Quadriplegia
B. Cerebellar functions	
0	Normal

1	Abnormal signs without disability
2	Mild ataxia
3	Moderate truncal or limb ataxia
4	Severe ataxia all limbs
5	Unable to perform coordinated movements due to ataxia
C. Brainstem functions	
0	Normal
1	Signs only
2	Moderate nystagmus or other mild disability
3	Severe nystagmus, marked extraocular weakness, or moderate disability of other cranial nerves
4	Marked dysarthria or other marked disability
5	Inability to swallow or speak
D. Sensory functions	
0	Normal
1	Vibration or figure-writing decrease only, in 1 or 2 limbs
2	Mild decrease in touch or pain or position sense, and/or moderate decrease in vibration in 1 or 2 limbs, or vibratory decrease alone in 3 or 4 limbs
3	Moderate decrease in touch or pain or position sense, and/or essentially lost vibration in 1 or 2 limbs, or mild decrease in touch or pain, and/or moderate decrease in all proprioceptive tests in 3 or 4 limbs
4	Marked decrease in touch or pain or loss of proprioception, Alone or combined, in 1 or 2 limbs or moderate decrease in touch or pain and/or severe proprioceptive decrease in more than 2 limbs
5	Loss (essentially) of sensation in 1 or 2 limbs or moderate Decrease in touch or pain and/or loss of proprioception for most of the body below the head
6	Sensation essentially lost below the head
E. Bowel and bladder functions	
0	Normal
1	Mild urinary hesitancy, urgency, or retention
2	Moderate hesitancy, urgency, retention of bowel or bladder, or rare urinary incontinence
3	Frequent urinary incontinence
4	In need of almost constant catheterization
5	Loss of bladder function
6	Loss of bowel and bladder function
F. Visual (or optic) functions	
0	Normal
1	Scotoma with visual acuity (corrected) better than 30/20
2	Worse eye with scotoma with maximal visual acuity (corrected) of 20/30 to 20/59
3	Worse eye with large scotoma, or moderate decrease in fields, but with maximal visual acuity (corrected) of 60/20 to 20/99
4	Worse eye with marked decrease of fields and maximal acuity (corrected) of 20/100 to 20/200; grade 3 plus maximal acuity of better eye of 20/60 or less
5	Worse eye with maximal visual acuity (corrected) less than 20/200; grade 4 plus maximal acuity of better eye of 20/60 or less
6	Grade 5 plus maximal visual acuity of better eye of 60/20 or less
G. Cerebral (or mental) functions	
0	Normal
1	Mood alteration only (does not affect EDSS score)

2	Mild decrease in mentation
3	Moderate decrease in mentation
4	Marked decrease in mentation
5	Chronic brain syndrome—severe or incompetent

2.3 Blood sample

Blood sample was taken before and after one and six weeks of the study to analyze Serum random blood sugar and WBC counts.

2.4 Biochemical Assay Methods

2.4.1 Measurement of Serum Glucose Level

Serum glucose level evaluated using a ready-made kit for this purpose, according to the method of Borham and Trindoe.^[11]

2.4.2 Measurement of WBC count

Automated equipment to carry out complete blood counts developed in the 1950s and 1960s.^[12]

2.5 Statistical Analysis

Data are expressed as means \pm SE. Statistics were performed using statistical software (Minitab17). Differences from baseline were assessed by the paired student's t test. P-value of <0.05 was considered significant.

RESULTS AND DISCUSSION

Forty patients presented to treatment, 20 in group1 (500mg methylprednisolone) and 20 in group2 (1000mg methylprednisolone). There were no apparent differences between the three groups with respect to demographic data. (Table5).

Table (5): Demographic data and baseline characteristics of the patients.

Data	Group 1	Group 2	P-value
Age (yrs.)	30.95 \pm 1.42	33.00 \pm 1.35	0.303
No. of subjects	20	20	-----
Gender	17 female 3 male	15 female 5 male	-----
EDSS	2.650 \pm 0.206	2.450 \pm 0.248	0.539
Dose	500 mg	1000mg	-----
Duration of therapy	5 days	5 days	-----
MS Duration(yrs.)	3.508 \pm 0.867	2.850 \pm 0.535	0.522
Weight (kg)	70.80 \pm 2.10	73.30 \pm 2.09	0.403

Data are expressed as Mean \pm SE * significant when $p<0.05$

3.1. Effect of methylprednisolone on random blood sugar (RBS) in treated patients with MS

Table 6 and fig. 1 showed a non-significant difference in RBS among treated groups at pretreatment ($p=0.967$). One week after treatment group 1 showed a non-significant difference in RBS ($P=0.428$) from baseline value. However, a significant increase in RBS was observed in group 2 ($P=0.038$) after one week of therapy compared to pretreatment value. After six weeks of treatment, there was a non-significant change in RBS for patients in both treated groups compared to pre-treatment ($P=0.882$), ($P=0.902$) respectively.

Over all, there was statistically non-significant variation in RBS after one and six weeks of treatment among groups ($P=0.363$), ($P=0.742$) respectively.

Fardet L et al. and Martinelli V et al.^{[13],[14]} they found high dose (1000mg) of methylprednisolone cause significant increase in RBS.

Table 6: Effect of treatment with 500 mg and 1000 mg IV methylprednisolone on RBS in patients with MS after 1 and 6 weeks of treatment.

Group	Pre-Treatment	RBS mg/dl			% of Change
		After 1wks	% of Change	After 6wks	
Group 1	137.20±5.52	144.30± 6.91	4.92%	136.15±4.32	0.77%
Group 2	136.90± 4.62	165.7±12.2*	17.38%	136.50±3.93	0.29%

Data are expressed as Mean±SEM; *significantly difference compares to pretreatment within the same group ($p<0.05$).




Fig.1: Histogram showing the effect of methylprednisolone doses on random blood sugar (RBS) in treated patients with MS after 1 and 6 weeks of treatment.

3.2. Effect of methylprednisolone doses on WBC counts

Table 7 and fig. 2 showed a non-significant difference in WBC counts among treated groups at pretreatment ($p = 0.767$). One week after treatment, there was a non-significant difference in WBC counts in group 1 and group 2 ($P = 0.943$) ($P = 0.231$) compared to groups at pretreatment respectively. Similarly, after six weeks of treatment, there was a non-significant change in WBC counts for patients in both treated groups compared to pre-treatment ($P = 0.983$) and ($P = 0.110$) respectively.

However, there was statistically non-significant difference in WBC counts among groups after one and six weeks of treatment ($P = 0.430$), ($P = 0.268$) respectively.

As found Barnes D, et al.^{[15][16]} and Selin A, et al. there was a non-significant change in WBC counts among patients treated with methylprednisolone.

Table 7: Effect of treatment with 500 mg and 1000 mg methylprednisolone on WBC counts in patients with MS after 1, 6 weeks of treatment

Groups	WBC counts cell/ m^3			% of Change
	Pre Treatment	After 1wks	After 6wks	
Group 1	7.836 ± 0.369	7.874 ± 0.376	7.848 ± 0.436	0.153%
Group 2	7.687 ± 0.343	8.285 ± 0.353	8.461 ± 0.327	10.069%

Data expressed as Mean \pm SEM




Fig.2: Histogram showing the effect of treatment with 500 mg and 1000 mg IV methylprednisolone on WBC count in patients with MS after 1 and 6 weeks of treatment.

3. 3. Side effects of methylprednisolone doses

Table 8 showed the adverse effects associated with the treatment in both groups therapy after one week of treatment.

It was clear from the table that different types of side effects seen in both groups and the occurrence of these effect various among groups. Group 2 had the higher rate of frequency of these effects than group 1. The side effects encountered in both groups considered mild to moderate in nature and did not require discontinuation of the medications.

The following side effects reported more frequently among the groups; hyperglycemia, dyspepsia, infection and headache.

This result was in agreement with Fierro B, *et al*^[17] and Martinelli V, *et al*^[18], whom found that hyperglycemia and urinary tract infection was the most common side effects in the patient treated with methylprednisolone.

Lublin F^[19] and Burton JM, *et al*^[20] agree with the results of ours research that insomnia was equal in both groups, while mood disturbance, nausea/vomiting and headache is higher in group 2 but non-significant difference between both groups are obtained.

Table 8: Side Effects of Methylprednisolone.

side effects	Group 1	Percentage	Group 2	Percentage
Hyperglycemia (transient)	1	5%	3	15%
Dyspepsia	2	10%	3	15%
Infection	1	5%	3	15%
Insomnia	2	10%	2	10%
Mood disturbance	1	5%	2	10%
Headache	1	5%	2	10%
Nausea/vomiting	0	0%	1	5%
Flushing	0	0%	0	0%
Pancreatitis	0	0%	0	0%
Cataracts	0	0%	0	0%
Myalgia	0	0%	0	0%
Diabetes	0	0%	0	0%
Weight gain/edema	0	0%	0	0%

CONCLUSIONS

According to the data of the present study, we can conclude that:

1. Methylprednisolone in a dose 1000mg had a significant increase in RBS while dose 500mg had no effect on RBS.

2. Methylprednisolone in a dose 1000mg had significant and more frequent side effects than 500mg.
3. Methylprednisolone in a dose 1000mg and 500mg had no effect on WBC count.

ACKNOWLEDGEMENT

The present work was abstracted from M Sc theses submitted to the Department of Clinical Pharmacy, College of Pharmacy, University of Baghdad. The authors gratefully thank multiple sclerosis unite, Baghdad Teaching Hospital, Medical City for supporting the project.

REFERENCE

1. Compston A, Coles A. "Multiple sclerosis". Lancet. 2008; 372(9648): 17–1502.
2. Compston A, Coles A. "Multiple sclerosis". Lancet. 2002; 359(9313): 31–1221.
3. Lublin FD, Reingold SC, Cohen JA, *et al.* "Defining the clinical course of multiple sclerosis ". Neurology. 2014; 83(3): 86-278.
4. Alastair Compston, Christian Confavreux, Hans Lassmann, *et al.* McAlpine's Multiple Sclerosis, 4th edition, Elsevier Inc, 2006; CH.6: P 287-346.
5. Rudick RA, Cutter G, Reingold S. "The multiple sclerosis functional composite: a new clinical outcome measure for multiple sclerosis trials". Mult. Scler. 2002; 8(5): 65–359.
6. Coles AJ, Twyman CL, Arnold DL, *et al.* "Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial". Lancet. 2012; 380(9856): 39-1829.
7. Kaufman DI, Trobe JD, Eggenberger ER, *et al.* "Practice parameter: The role of corticosteroids in the management of acute monosymptomatic optic neuritis". Neurology. 2000; 54: 2039–2044.
8. Zivadinov R, Rudick RA, De Masi R, *et al.* "Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS". Neurology, 2001; 57: 1239–1247.
9. Anderson PB, Goodkin DE. Glucocorticosteroid therapy for multiple sclerosis: a critical review. J Neurol Sci., 1998; 160: 16–25.
10. Fleming, JO. "Helminth therapy and multiple sclerosis". International Journal for Parasitology, 2013; 43(3–4): 259–274.
11. Barham D and Trinder P. "An improved color reagent from the determination of blood glucose by the oxidative system". Analyst, 1972; 97: 142-145.

12. Daniel Heikali, Dino Di Carlo." A Niche for Microfluidics in Portable Hematology Analyzers ". Journal of the Association for Laboratory Automation. 2010; 15(4): 319-328.
13. Fardet L, Kassas A, Cabane J and Flahault A. Corticosteroid-induced adverse events in adults: frequency, screening and prevention. *Drug Saf.* 2007; 30(10): 861-881.
14. Martinelli V, Pulizzi A, Annovazzi P, *et al.* A single blind randomised MRI study comparing high-dose oral and intravenous methylprednisolone in treating MS relapses. 2009; 73: 1842–1848.
15. Barnes D, Hughes RAC, Morris RW, *et al.* Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. *Lancet.* 1997; 349: 902–906.
16. Selin A, Mualla C, Murat T, *et al.* Myeloprotective Effect of Short-Course High-Dose Methylprednisolone Treatment Before Consolidation Therapy in Children With Acute Myeloblastic Leukemia. *American Journal of Hematology.* 2005; 80: 1–5.
17. Fierro B, Salemi G, Brighina F. *et al.* A transcranial magnetic stimulation study evaluating methylprednisolone treatment in multiple sclerosis. *Acta Neurol Scand.* 2002; 105: 152–157.
18. Martinelli V, Rocca MA, Annovazzi P, *et al.* A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS. *Neurology,* 2009; 73: 1842–1848.
19. Lublin F. Oral Mega dose Corticosteroid Therapy of Acute Exacerbations of Multiple Sclerosis (OMEGA). www.clinicaltrials.gov, 2007.
20. Burton JM, O'Connor PW, Hohol M, *et al.* Oral versus Intravenous Steroids for Treatment of Relapses in Multiple Sclerosis. *Cochrane Collaboration.* 2009.